(2)
NEW YORK CITY (dpa-AFX) - Today s Daily Dose brings you news about KemPharm scoring regulatory nod for its ADHD drug, expanded FDA approval for Pfizer s Lorbrena, United Therapeutics scrapping the development of Trevyent, Vir Biotechnology closing the enrollment in VIR-7831 arm of ACTIV-3 trial, and Takeda securing global rights to Ovid s investigational medicine Soticlestat.
Read on.
1.KemPharm Scores FDA Nod For ADHD Drug
KemPharm Inc. (KMPH) soared more than 42% on Wednesday, following FDA approval of AZSTARYS (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older.
United Therapeutics Corporation (NASDAQ:UTHR) - United Therapeutics Pulls Plug On Trevyent Development
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Healthcare News: Global Antihypertensives Market Size Key Trends Challenges, Top Key Players and Fo
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
6.3. Systemic Scleroderma Treatment Market - North America
6.3.1. North America: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)
6.3.2. Systemic Scleroderma Treatment Market - U.S.
6.3.2.1. U.S.: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)
6.3.3. Systemic Scleroderma Treatment Market - Canada
6.3.3.1. Canada.: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)
6.4. Systemic Scleroderma Treatment Market - Europe
6.4.1. Europe: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)
6.4.2. Systemic Scleroderma Treatment Market - UK
6.4.2.1. UK: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)
6.4.3. Systemic Scleroderma Treatment Market - France
6.4.3.1. France: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)
Operator
Good morning, and welcome to the United Therapeutics Corporation Fourth Quarter 2020 Earnings Call. My name is Kenzie, and I will be your conference operator today. [Operator Instructions]
I will now turn the conference call over to Mr. Dewey Steadman, Head of Investor Relations at United Therapeutics.
Dewey Steadman
Head of Investor Relations
Good morning. It s my pleasure to welcome you to the United Therapeutics Corporation Fourth Quarter 2020 Earnings Call. Accompanying me on today s call are Dr. Martine Rothblatt, our Chairman and Chief Executive Officer; Mr. Michael Benkowitz, our President and Chief Operating Officer; Mr. James Edgemond, our Chief Financial Officer and Treasurer; and Dr. Leigh Peterson, Vice President of Product Development. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially.